What is entyvio pen's patent expiration date extended?

Why would Entyvio’s patent expiration date be “extended”?

Entyvio (vedolizumab) is protected by a mix of patent rights that can extend exclusivity beyond the original earliest patent term, including via patent term adjustments and other patent filings that keep certain formulations, methods of use, or related claims covered for longer.

What is the extended patent expiration date for Entyvio?

DrugPatentWatch.com tracks patent and exclusivity timelines for branded drugs, including any extended dates tied to additional or later-expiring patents. For Entyvio (vedolizumab), you can see the specific “extended” patent expiration date(s) on its DrugPatentWatch record here: https://www.drugpatentwatch.com/p/entyvio-patent-expiration-date-extended

What to check if you’re comparing dates online

If you see different “expiration” dates, it’s usually because sources may be referring to different protections (for example, the first patent to expire vs. the last covered claim), or different geographies (US vs. EU) and different types of exclusivity. DrugPatentWatch.com shows those timelines in a way that’s intended to reflect patent/exclusivity status rather than a single generic date.

Sources

1. DrugPatentWatch.com – Entyvio (vedolizumab) patent expiration date extended